Rallybio Corporation
NASDAQ:RLYBBiotechnology
+$0.01 today
- Market cap
- $82.16M
- Beta
- -0.88
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.37
Volume 0.03M
Average 0.25M
RLYB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Rallybio CorporationNASDAQ: RLYB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $3K fell 89.3% year over year, behind the -46.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.
Context
- Depreciation & amortization amounted to 10.7% of revenue in FY2025, down 9.9 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -89.3% toward the trailing-twelve-month pace of -46.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 92K USD
- Year-over-year change
- -29.8%
- 4-year CAGR
- -4.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 92K | -29.8% |
| FY2024 | 2024-12-31 | 131K | -12.7% |
| FY2023 | 2023-12-31 | 150K | -10.2% |
| FY2022 | 2022-12-31 | 167K | +53.2% |
| FY2021 | 2021-12-31 | 109K | — |
Depreciation & Amortization vs competitors
How RLYB compares with its peers on the latest reported figures
- RLYB's LTM Mar 2026 depreciation & amortization of $67K is the smallest of the 4 companies compared; the peer median is $549K.
- Its year-over-year change of -46.0% is the 3rd highest of 4, against a peer median of -36.9%.
- Depreciation & amortization amounts to 7.8% of revenue for RLYB, versus a peer median of 274.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.22M | +6.8% | +9.9% | — | |
| LTM Jun 2026 | $549K | -51.2% | -60.0% | 549.0% | |
| LTM Mar 2026 | $305K | -36.9% | +1.9% | 0.6% | |
| LTM Mar 2026 | $67K | -46.0% | -18.0% | 7.8% | |
| Peer median (excluding RLYB) | $549K | -36.9% | +1.9% | 274.8% | |
Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47.01M) | (66.65M) | (74.56M) | (57.78M) | (8.98M) |
| Depreciation & Amortization | 109K | 167K | 150K | 131K | 92K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.65M | 9.5M | 10.92M | 7.99M | 5.31M |
| Change in Working Capital | (3.78M) | (936K) | 4.28M | (258K) | (4.19M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (976K) | 487K | (99K) | (698K) | (152K) |
| Other Working Capital | (2.8M) | (1.42M) | 4.38M | 440K | (4.04M) |
| Other Non-Cash Items | 1.51M | 640K | (1.05M) | 627K | (22.05M) |
| Operating Cash Flow | (45.53M) | (57.28M) | (60.27M) | (49.28M) | (29.81M) |
| Capital Expenditures | (333K) | (54K) | (12K) | 0 | 0 |
| Acquisitions (Net) | (2M) | (300K) | (2.25M) | (2M) | 0 |
| Purchases of Investments | (2M) | (201.32M) | (110.66M) | (48.93M) | (17.7M) |
| Sales of Investments | 2M | 89.5M | 138.33M | 84.43M | 46.47M |
| Other Investing Activities | (2K) | 0 | 2.25M | 0 | 18.5M |
| Investing Cash Flow | (2.33M) | (112.17M) | 27.66M | 33.49M | 47.27M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 86.2M | 51.53M | 143K | 5.41M | 16K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.23M) | (455K) | 0 | (206K) | 0 |
| Financing Cash Flow | 82.97M | 51.08M | 143K | 5.2M | 16K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 35.1M | (118.38M) | (32.46M) | (10.59M) | 17.47M |
| Free Cash Flow | (45.87M) | (57.34M) | (60.28M) | (49.28M) | (29.81M) |
Rallybio Corporation
NASDAQ:RLYB
Intrinsic Alpha fair value
Locked
Current Price
$15.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.